These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33459210)

  • 1. Successful dalbavancin use in preventing reactivation of
    Dell'Orso G; Faraci M; Giardino S; Mariani M; Mesini A; Castagnola E
    J Chemother; 2021 Nov; 33(7):517-518. PubMed ID: 33459210
    [No Abstract]   [Full Text] [Related]  

  • 2. Unsuccessful treatment of methicillin-resistant Staphylococcus aureus endocarditis with dalbavancin.
    Steele JM; Seabury RW; Hale CM; Mogle BT
    J Clin Pharm Ther; 2018 Feb; 43(1):101-103. PubMed ID: 28628223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of teicoplanin in Staphylococcus aureus catheter-related tricuspid endocarditis during severe neutropenia.
    Durand-Gasselin B; Lortholary O; Tod M; Guillevin L; Casassus P
    Ann Med Interne (Paris); 1997; 148(7):502-3. PubMed ID: 9538389
    [No Abstract]   [Full Text] [Related]  

  • 4. Dalbavancin treatment of methicillin-susceptible Staphylococcus aureus pyomyositis with torpid evolution: a case report.
    Álvarez Otero J; Sanjurjo Rivo A; Lamas Ferreiro JL; de la Fuente Aguado J
    Rev Esp Quimioter; 2019 Jun; 32(3):276-277. PubMed ID: 31037932
    [No Abstract]   [Full Text] [Related]  

  • 5. Dalbavancin was effective and safe after one year of treatment in a complicated osteoarticular infection caused by methicillin-resistant Staphylococcus aureus.
    Matesanz M; Poza A; Iñurrieta A; Fernández-Diaz E; Arroyo M; Domínguez I; Candel FJ
    Rev Esp Quimioter; 2021 Aug; 34(4):396-399. PubMed ID: 33956412
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dalbavancin and its use in the treatment of methicillin-resistant Staphylococcus aureus - induced upper limb phlegmon].
    Zahornacký O; Novotný M
    Klin Mikrobiol Infekc Lek; 2020 Jun; 26(2):51-53. PubMed ID: 33389741
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Plota M; Papadimitriou-Olivgeris M; Kolonitsiou F; Tsiata E; Spiliopoulou I; Assimakopoulos SF; Marangos M
    J Med Microbiol; 2021 Sep; 70(9):. PubMed ID: 34559042
    [No Abstract]   [Full Text] [Related]  

  • 8. Usefulness of therapeutic drug monitoring in estimating the duration of dalbavancin optimal target attainment in staphylococcal osteoarticular infections: a proof-of-concept.
    Cojutti PG; Rinaldi M; Gatti M; Tedeschi S; Viale P; Pea F
    Int J Antimicrob Agents; 2021 Nov; 58(5):106445. PubMed ID: 34614441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with dalbavancin in a patient with septic thrombophlebitis of the internal jugular vein due to Staphylococcus aureus after insertion of an implantable cardioverter defibrillator.
    Martínez-Sanz J; Gijón de la Santa L; Torralba M
    Enferm Infecc Microbiol Clin (Engl Ed); 2018; 36(6):389-390. PubMed ID: 29132942
    [No Abstract]   [Full Text] [Related]  

  • 10. Dalbavancin for the treatment of acute bacterial skin and skin structure infections.
    Esposito S; Noviello S; Leone S
    Infez Med; 2015 Dec; 23(4):313-7. PubMed ID: 26700080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful treatment of methicillin-sensitive Staphylococcus aureus tricuspid-valve endocarditis with dalbavancin as an outpatient in a person who injects drugs: A case report.
    Hakim A; Braun H; Thornton D; Strymish J
    Int J Infect Dis; 2020 Feb; 91():202-205. PubMed ID: 31841726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-biofilm activity of dalbavancin against methicillin-resistant
    Silva V; Miranda C; Bezerra M; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    J Chemother; 2021 Nov; 33(7):469-475. PubMed ID: 33904369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dalbavancin treatment of prosthetic knee infection due to oxacillin-resistant Staphylococcus epidermidis.
    Ramírez Hidalgo M; Jover-Sáenz A; García-González M; Barcenilla-Gaite F
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Feb; 36(2):142-143. PubMed ID: 28600171
    [No Abstract]   [Full Text] [Related]  

  • 14. Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011-2016).
    Pfaller MA; Flamm RK; Castanheira M; Sader HS; Mendes RE
    Int J Antimicrob Agents; 2018 Apr; 51(4):608-611. PubMed ID: 29277526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of dalbavancin, alone and in combination with rifampicin, against meticillin-resistant Staphylococcus aureus in a foreign-body infection model.
    Baldoni D; Furustrand Tafin U; Aeppli S; Angevaare E; Oliva A; Haschke M; Zimmerli W; Trampuz A
    Int J Antimicrob Agents; 2013 Sep; 42(3):220-5. PubMed ID: 23880168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of dalbavancin in a rat model of methicillin-resistant Staphylococcus aureus (MRSA)-osteomyelitis.
    Silva V; Miranda C; Antão HS; Guimarães J; Prada J; Pires I; Maltez L; Pereira JE; Capelo JL; Igrejas G; Poeta P
    Int J Antimicrob Agents; 2020 Jul; 56(1):106021. PubMed ID: 32439480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New antimicrobial agents for methicillin-resistant Staphylococcus aureus.
    Kollef MH
    Crit Care Resusc; 2009 Dec; 11(4):282-6. PubMed ID: 20001879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
    Pfaller MA; Mendes RE; Sader HS; Castanheira M; Flamm RK
    J Glob Antimicrob Resist; 2017 Dec; 11():4-7. PubMed ID: 28735053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. French national cohort of first use of dalbavancin: A high proportion of off-label use.
    Dinh A; Duran C; Pavese P; Khatchatourian L; Monnin B; Bleibtreu A; Denis E; Etienne C; Rouanes N; Mahieu R; Bouchand F; Davido B; Lotte R; Cabaret P; Camou F; Chavanet P; Assi A; Limonta S; Lechiche C; Riou R; Courjon J; Illes G; Lacassin-Beller F; Senneville E;
    Int J Antimicrob Agents; 2019 Nov; 54(5):668-672. PubMed ID: 31400471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First vanguard anti-MRSA agent approved.
    Fox JL
    Nat Biotechnol; 2014 Jul; 32(7):603. PubMed ID: 25004211
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.